SVB Wealth’s Viking Therapeutics VKTX Stock Holding History

SVB Wealth’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-725	Closed	-$17.5K	–	1593
2025 Q1	$17.5K	Buy	+725	New	+$22.9K	﹤0.01%	778

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

SVB Wealth's VKTX Position: Q2 2025 in Review

SVB Wealth sold out of Viking Therapeutics (VKTX) in Q2 2025, closing a stake of 725 shares — an estimated $17.5K sold.

SVB Wealth first reported a position in VKTX in Q1 2025 and held it in 1 quarter. The position peaked at $17.5K in Q1 2025. 391 funds tracked by Wall St. Rank hold VKTX as of Q2 2025.

SVB Wealth reported no remaining Viking Therapeutics position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 725 Viking Therapeutics shares in Q2 2025, an estimated $17.5K.
SVB Wealth first reported a position in Viking Therapeutics in Q1 2025 and held it in 1 quarter.
SVB Wealth's Viking Therapeutics position peaked at $17.5K in Q1 2025.
391 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.